Novopharm received its NOC for a generic version of LOVENOX ("Novo-enoxaparin") on February 28, 2005, and Aventis has commenced an action for patent infringement against Novopharm. Judge dismisses Aventis' motion for an interlocutory or interim injunction to restrain Novopharm from, among other things, selling Novo-enoxaparin pending trial. Judge finds that Aventis failed to demonstrate that it will suffer irreparable harm if an injunction is not issued. Aventis has appealed.
I think Teva will eventually launch but having it not developed in house would lead me to think it is more probable to be later then sooner.
Whomever contacts Teva next how about just saying I am a Momenta shareholder can you tell me when you think you will get approval to launch... then we can analyze how believable their reply is .
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
. 
